The UN Sustainable Development Goals, which support the implementation of universal health coverage by 2030, recognise that more equitable and timely access to health interventions such as medicines, vaccines, diagnostics and therapies is an important driver of good health and improved lives. In the words of the World Health Organisation, universal health coverage can only be achieved when there is affordable access to safe, effective and quality medicines and health products. Recent years have seen significant progress, made through collaboration between different actors and using various mechanisms and business models. Cambridge Enterprise, supported by the University of Cambridge, wishes to play its role.
Cambridge Enterprise licences anticipate that licensees, upon achieving the first regulatory approval for a new medicine, will discuss and where possible agree a plan to support affordable access for the licensed product(s) in low and middle income countries, such as through licensing or partnerships including with non-profit organisations, with strategies and timelines.
